AdvanCell
AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment.
About AdvanCell
AdvanCell is a clinical-stage radiopharmaceutical company that develops novel cancer therapeutics. It develops alpha-emitting isotopes attached to molecules that deliver cytotoxic radiation directly to tumors at the molecular level to allow healthcare providers to provide safe and effective treatment for multiple forms of cancer.
Company Facts
- Headquarters
- Sydney
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- late_stage_venture
- Total Funding
- $137,892,644
- Last Funding Type
- grant
- Last Funding Date
- 2025-04-13
- Website
- advancell.com.au
Industries & Categories
Biotechnology, Clinical Trials, Oncology, Pharmaceutical
Social Links
Canonical: https://fsome.com/organization/advancell-95920 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.